Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03158883 · ClinicalTrials.gov registry record · Early Phase 1
UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients
A Early Phase 1 study, sponsored by Megan Daly, MD.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT03158883 is a Early Phase 1 study that has completed, run by Megan Daly, MD. The registered enrollment target is 8 participants.
The verdict
NCT03158883, a Early Phase 1 study, has completed, sponsored by Megan Daly, MD.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a pilot, single center, open-label study to examine the ORR, safety, and toxicity of avelumab in combination with SAR in non-responding and progressing NSCLC patients previously treated with a PD-1 Inhibitor.
Interventions
- DRUG Avelumab
- RADIATION Stereotactic ablative radiotherapy (SAR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2017-05-17 |
| Est. Completion | 2020-06-24 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03158883
The ClinicalTrials.gov registry entry for NCT03158883 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Megan Daly, MD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Avelumab is the first listed.
NCT03158883 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03158883 about?
NCT03158883 is a clinical study titled "UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients". This is a pilot, single center, open-label study to examine the ORR, safety, and toxicity of avelumab in combination with SAR in non-responding and progressing NSCLC patients previously treated with a PD-1 Inhibitor.
What is the current status of trial NCT03158883?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2017-05-17. Estimated completion is 2020-06-24.
What interventions are being tested in trial NCT03158883?
The interventions under investigation include: Avelumab (DRUG), Stereotactic ablative radiotherapy (SAR) (RADIATION).
Who is sponsoring clinical trial NCT03158883?
This trial is sponsored by Megan Daly, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.